Company Overview - ProKidney Corp. is a late clinical-stage biotech company focused on developing a first-in-class cell therapy candidate for chronic kidney disease (CKD) [1] - The company was founded in 2015 and has a decade of research behind it [6] - ProKidney's lead product candidate, rilparencel (REACT®), is an autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for preserving kidney function in diabetic patients at high risk of kidney failure [6] - Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA [6] Upcoming Events - ProKidney management will participate in two healthcare conferences in November 2024 [1] - The first event is the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 13, 2024, at 10:30 am ET [3] - The second event is the Jefferies London Healthcare Conference on November 20, 2024, at 10:00 am GMT [4] - Live webcasts of these events will be accessible through the "Events" section of ProKidney's website, with replays available for 90 days post-event [4] Investor Engagement - ProKidney management will host one-on-one meetings during the conferences [5] - Interested investors are encouraged to contact their Guggenheim and Jefferies representatives to schedule meetings [5]

WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA. The titles for the accepted abstracts are provided below and accessib ...

WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024. UBS Virtual Organ Restoration Day Date: Tuesday, October 15, 2024 Time: 9:00am ET Format: Fireside ...

Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority market Discontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first ...

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a leading late clinical-stage biotech company focused on the development of a first-inclass cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024. Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40560 ProKidney Corp. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-1586514 ( State or other jurisdicti ...

Exhibit 99.1 ProKidney Reports Business Updates and Second Quarter 2024 Financial Results • Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKD • Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials • Closed $140 million upsized underwritten public offering and concurrent registered direct offering • Ended the second quarter with $431.5 million in cash and cash equivalents and marketable securitie ...

Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKD Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials Closed $140 million upsized underwritten public offering and concurrent registered direct offering Ended the second quarter with $431.5 million in cash and cash equivalents and marketable securities, supporting operations through projected Phase 3 enrollment completion in mid-2026 WINSTON-SALEM ...

Source: ProKidney Corp. INVESTOR INQUIRIES: LifeSci Advisors, LLC Daniel Ferry Daniel@lifesciadvisors.com A shelf registration statement relating to the Class A ordinary shares was filed with the Securities and Exchange Commission and was declared effective on November 30, 2023 (File No. 333-275701). A preliminary prospectus supplement, a final prospectus supplement and the accompanying prospectus relating to the underwritten public offering have been filed with the SEC and are available on the website of t ...

ProKidney currently intends to use the net proceeds from the underwritten public offering and the concurrent registered direct offering for clinical trial costs and other research and development expenses, continued investment in its drug development platform, for its pre-commercial and commercial activities, including its commercial manufacturing facility, and for other general corporate purposes, including for working capital, capital expenditures and general and administrative expenses. A shelf registrat ...